Autologous bone marrow-derived mononuclear cell therapy (Shanghai Changzheng Hospital)

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameAutologous bone marrow-derived mononuclear cell therapy (Shanghai Changzheng Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsSpinal Cord Injuries

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPending

Originator CompaniesShanghai Changzheng Hospital

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Changzheng Hospital

Inactive CompaniesN/A

Active IndicationsSpinal Cord Injuries

Inactive IndicationsN/A

Other Information

ATC CodeN/A